The U.S. Food and Drug Administration on Nov. 17 approved Lembaz (adrabetadex) injection, the first treatment shown to help people with a severe form of Niemann-Pick disease type C live longer. Lembaz is approved to reduce the risk of death in adult and pediatric patients who weigh at least 7 kilograms, about 15 pounds, and whose neurological symptoms began before age 6, also known as infantile-onset NPC, the agency said.

"For families living with Niemann-Pick disease type C, today's approval marks an important milestone," said Acting FDA Commissioner Kyle Diamantas. "For the first time, there is a treatment shown to help adults and children with this serious disease live longer, and we are committed to continuing to support the development of therapies for the rare disease community." NPC is a rare, inherited lysosomal storage disorder affecting an estimated 1 in 150,000 people, in which the body cannot properly process cholesterol and other fats inside cells. Over time, these substances accumulate, particularly in the brain, causing progressive neurological decline, including loss of movement, coordination, and the ability to swallow, the FDA said. Patients whose neurological symptoms begin before age 6 face the most serious form of the disease.

Prior to this approval, two therapies were approved for NPC, but neither has been shown to reduce the risk of death, and both carry age and weight restrictions that limit access for the youngest and most seriously affected patients, the FDA said. A trained healthcare provider gives Lembaz as an injection directly into the spinal canal, an intrathecal injection, every two weeks. To assess whether Lembaz reduced the risk of death, the FDA examined the survival of 36 patients treated with Lembaz across three clinical studies and an expanded access program, all of whom had neurological manifestations of NPC that occurred prior to age 6. Patients treated with Lembaz had longer overall survival compared with the matched external control group, with a 55% reduction in the risk of death. The median survival time was 8.5 years for the treated group compared with 4.9 years in the control group. This survival benefit was observed regardless of whether patients were also taking miglustat, a therapy used off-label in NPC, the agency said.

The most common side effects include problems with hearing, balance and coordination, fatigue, vomiting, back pain, headache, fever, diarrhea, nausea, and cough. Lembaz carries a boxed warning for hearing impairment, including permanent hearing loss. A comprehensive hearing evaluation should be performed before starting treatment and regularly throughout, and dose adjustments may be needed based on those results, the FDA said. Lembaz received Breakthrough Therapy designation. The FDA granted approval to Mandos, LLC, a subsidiary of Beren Therapeutics, PBC. This story reports the official Nov. 17 approval and labeled risks; it is not medical advice, and patients should rely on the FDA labeling and their clinicians. It is a distinct rare-disease approval from the Nov. 18 Infilbray decision for Type 3 Gaucher disease.